tert-Butyl N-[2-(3-bromophenoxy)ethyl]-N-methylcarbamate

Catalog No. :
ACPHGY730
CAS No. :
2222512-11-8
Molecular Formula :
C14H20BrNO3
Molecular Weight :
330.22

IUPAC Name:tert-butyl (2-(3-bromophenoxy)ethyl)(methyl)carbamate

tert-Butyl N-[2-(3-bromophenoxy)ethyl]-N-methylcarbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$117.00Login to see priceInquiryInquiry
1g98%$252.00Login to see priceInquiryInquiry
5g98%$716.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl N-[2-(3-bromophenoxy)ethyl]-N-methylcarbamate
IUPAC Nametert-butyl (2-(3-bromophenoxy)ethyl)(methyl)carbamate
Molecular FormulaC14H20BrNO3
Molecular Weight330.22
SMILESO(C1C=CC=C(C=1)Br)CCN(C)C(=O)OC(C)(C)C
InChI KeyUIHLOIBWPOSSTA-UHFFFAOYSA-N
Synonymtert-Butyl N-[2-(3-bromophenoxy)ethyl]-N-methylcarbamate;Carbamic acid, N-[2-(3-bromophenoxy)ethyl]-N-methyl-, 1,1-dimethylethyl ester
CAS No.2222512-11-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACPHGY730 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTBEG962 route compound structure diagram
    ACTBEG96257561-39-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPHGY730 route product structure diagram
    ACPHGY7302222512-11-8
Inquiry

2. ACPHGY730 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKJSX207 route compound structure diagram
    ACKJSX2071098107-26-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPHGY730 route product structure diagram
    ACPHGY7302222512-11-8
Inquiry

Comments (0)